Abstract library

81 results for "Kanakis".
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#2889 Transcatheter Arterial Embolization (TAE) of NEN Metastases: Efficacy and Predictors of Response
Introduction: Transcatheter-Arterial embolization (TAE) is an established regional, palliative treatment option for liver metastases in patients (pts) with neuroendocrine neoplasms (NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Eleni Armeni
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#2929 Type III Gastric Neuroendocrine Neoplasms: Is Local Excision Sufficient in Selected Cases?
Introduction: As per ENETS Guidelines, patients with type III gastric neuroendocrine neoplasms (t-III g-NEN), need to undergo partial or total gastrectomy. Data for less-extensive resections are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Mrs Klaire Exarchou
#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?
Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Julian Gertner
Keywords: telotristat
#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?
Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Julian Gertner
Authors: Gertner J, Groves J, Aziz B, Miah L, ...
Keywords: prrt
#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Julian Gertner
Keywords: homecare
#39 Specialist dietetic input and nutritional outcomes in Neuroendocrine Tumour Patients
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that are complex to manage and require a multidisciplinary approach. The most common primary sites are the small intestine and pancreas. The disease itself, as well as sequelae from surgery and medical therapy, can have a negative impact on patients’ nutritional status. Weight loss is known to be a poor prognostic indicator.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MRS CALEY L SCHNAID
Authors: Schnaid C, Khan M, Davies P, Jamieson A, ...
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis